How should we measure and report radiotherapy-induced xerostomia?

Seminars in Radiation Oncology

Volumn 13, Issue 3, 2003, Pages 226-234

  Eisbruch, Avraham ^a   Rhodus, Nelson ^b   Rosenthal, David ^b   Murphy, Barbara ^b   Rasch, Coen ^b   Sonis, Stephen ^b   Scarantino, Charles ^b   Brizel, David ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PERTECHNETIC ACID TC 99M;

CANCER RADIOTHERAPY; CONFERENCE PAPER; DISABILITY; FEEDING APPARATUS; FLOW RATE; HUMAN; NUTRITION; PAROTID GLAND DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RATING SCALE; SALIVARY GLAND FUNCTION; SALIVARY GLAND SCINTISCANNING; SALIVATION; SELF REPORT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP; SYMPTOMATOLOGY; TOXICITY; TRACHEOSTOMY; XEROSTOMIA;

EID: 0041853568     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)00033-X     Document Type: Conference Paper

References (66)

1. Cooper JS, Fu K, Marks J, et al: Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 31:1141-1164, 1995
2. Harrison LB, Zelefski MJ, Pfitzer DG, et al: Detailed quality of life assessment in patients treated with primary radiotherapy for cancer of the base of tongue. Head Neck 19:169-175, 1997
3. Bjordal K, Kaasa S, Mastekaasa A: Quality of life in patients treated for head and neck cancer: A follow up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 28:847-856, 1994
4. Jensen AB, Hanse O, Jorgensen K, et al: Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol 33:487-491, 1994
5. Beeken L, Calman F: A return to normal eating after curative treatment for oral cancer: Long term prospects. Oral Oncol 6:387-392, 1994
6. Christensen CM: Role of saliva in human taste perception, in Meiselman HR, Rivlin RS (eds): Clinical Measurement of Taste and Smell. New York, NY, MacMillan, 1986, pp 5-146
7. Brosvic GM, Hoey NE: Taste detection and discrimination performance of rats following selective desalivation. Physiol Behav 48:617-623, 1990
8. Balogh JM, Sutherland SE: Osteoradionecrosis of the mandible: A review. J Otolaryngol 18:245-250, 1989
9. Korsten MA, Rosman AS, Fishbein S, et al: Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. Am J Med 90:701-706, 1991
10. Kagami H, Hiramatsu Y, Hishida S, et al: Salivary growth factors in health and disease. Adv Dent Res 14:99-102, 2000
11. Awidi A, Homsi U, Kakail AI, et al: Double blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. Eur J Cancer 37:2010-2014, 2001
12. Dawes C: Rhythms in salivary flow rate and composition. Int J Chronobiol 2:253-279, 1974
13. Milne RW, Dawes C: The relative contributions of different salivary glands to the blood group activity of whole saliva in humans. Vox Sang 25:298-307, 1973
14. Tabak LA, Levine MJ, Mandel ID, et al: Role of salivary mucins in the protection of the oral cavity. J Oral Pathol 11:1-17, 1982
15. Levine MJ, Aguire A, Hatton MN, et al: Artificial salivas. J Dent Res 66:693-698, 1987
16. Mossman KL: Quantitative radiation dose-response relationships for normal tissue in man. II. Response of the salivary glands during radiation. Radiat Res 95:392-398, 1983
17. Ship JA, Eisbruch A, D'Hondt E, et al: Parotid sparing study in head and neck cancer patients receiving radiation therapy: One-year results. Dent Res 76:807-813, 1997
18. Shannon IL, Trodhal JN, Starcke EN: Radiosensitivity of the human parotid gland. Proc Soc Exp Biol Med 157:50-53, 1978
19. Kashima HK, Kirkham WR, Andrews JR: Postirradiation sialadenitis. Am J Roent Radium Ther Nucl Med 94:271-291, 1965
20. Stephens LC, Ang KK, Schultheiss TE, et al: target cell and mode of radiation injury in rhesus salivary glands. Radiother Oncol 7:165-174, 1986
21. Savage NW, Kruger BJ, Adkins KF: The effects of fractionated megavoltage irradiation on rat salivary glands: An assessment by electron microscopy. Aust Dent J 30:188-193, 1985
22. Navazesh M, Ship JI: Xerostomia: Diagnosis and treatment. Am J Otolaryngol 4:283-292, 1983
23. Tsuji H: Quantitative dose-response analysis of salivary function following radiotherapy using sequential RI-sialography. Int J Radiat Oncol Biol Phys 11:1603-1612, 1985
24. Van Acker F, Elamen P, Lambin P, et al: The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Commun 11:225-231, 2001
25. Navazesh M: Methods for collecting saliva. Ann. NY Acad Sci 694:72-77, 1993
26. Ericson S: An investigation of human parotid saliva secretion rate in response to different type of stimulants. Arch Oral Biol 14:591-594, 1969
27. Mandel ID: Sialochemistry in disease and clinical situations affecting salivary glands. Crit Rev Clin Lab Sci 12:321-366, 1980
28. Holmes JH: Changes in salivary flow produced by changes in fluid and electrolyte balance, in Sreebny LM, Meyer J (eds). Salivary Glands and Their Secretions. New York, NY, MacMillan Co, 1964, pp 177-195
29. Eisbruch A, Kim HM, Ten Haken R, et al: Dose, volume and function relationships in parotid glands following conformal and intensity modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45:577-587, 1999
30. O'Connell AC: Natural history and prevention of radiation injury. Adv Dent Res 14:57-61, 2000
31. Liem JH, Valdes-Olmos RA, Balm AJS, et al: Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumors. Eur J Nucl Med 23:1485-1490, 1996
32. Burlage FR, Coppes RP, Meertens H, et al: Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiother Oncol 61:271-274, 2001
33. Valdez JH, Atkinson JC, Ship JA: Maior salivary gland function in patients with radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 25:41-47, 1992
34. Coppes RP, Vissink A, Konings AWT: Comparison of radiosensitivity of rat parotid and submandibular glands after different radiation schedules. Radiother Oncol 63:321-328, 2002
35. Eisbruch A, Ship JA, Kim HM, et al: Partial irradiation of the parotid gland. Semin Radiat Oncol 11:234-239, 2001
36. Roesink JM, Moerland MA, Battersmann IJ, et al: Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head and neck region. Int J Radiat Oncol Biol Phys 51:938-946, 2001
37. Schilstra C, Meertens H: calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland. Int J Radiat Oncol Biol Phys 50:147-158, 2001
38. Chao KSC, Deasy SO, Markman J, et al: A prospective study of salivary function sparing in patients with head and neck cancers receiving intensity-modulated of three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 51:938-946, 2001
39. Maes A, Weltens C, Flamen P, et al: Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 53:203-211, 2002
40. Withers HR, Taylor JMG, Maciejewski B: Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 14:751-759, 1988
41. Marks JE, Davis CC, Gottsman VL, et al: The effects of radiation on parotid salivary function. Int J Rad Onc Biol Phys 7:1013-1019, 1981
42. Leslie MD, Dische S: The early changes in salivary gland function during and after radiotherapy given for head and neck cancer. Radiother Oncol 30:26-32, 1994
43. Franzen L, Funegard U, Ericson T, et al: Parotid gland function during and following radiotherapy of malignancies in the head and neck. Eur J Cancer 28:457-462, 1992
44. Eisbruch A, Kim HM, Terrell JE, et al: Xerostomia and its predictors following parotid-sparing irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 50:695-704, 2001
45. Wasserman T, Macowiac JI, Brizel DM, et al: Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48:1035-1039, 2000
46. Fox PC, Busch KA, Baum BJ: Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 115:581-584, 1987
47. Bjordal K, Kaas S: Psychometric validation of the EORTC core quality of life questionnaire and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 31:311-321, 1992
48. Hassan SJ, Weymuller EAL: Assessment of quality of life in head and neck cancer patients. Head Neck 15:485-496, 1993
49. Browman GP, Levine MN, Hodson DI, et al: The head and neck radiotherapy questionnaire: A morbidity/quality of life instrument for clinical trials of radiation therapy in head and neck cancer. J Clin Oncol 11:863-872, 1993
50. Cella DF, Bonomi AE: Measuring quality of life: 1995 update. Oncology 9:47-60, 1995 (suppl)
51. Terrell JE, Nanavati KA, Esclamado RM, et al: Head and neck cancer-specific quality of life: Instrument validation. Arch Otolaryngol Head Neck Surg 124:964-971, 1998
52. Trottti A, Johnson DI, Gwede C: Development of a head and neck companion module for the quality of life-radiation therapy instrument. Int J Radiat Oncol Biol Phys 42:257-261, 1998
53. LENT SOMA Tables. Radiother Oncol 35:17-60, 1995
54. Lee N, Xia P, Quivey JM, et al: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12-22, 2002
55. Ship JA, Fox PC, Baum BJ: How much saliva is enough? "Normal" function defined. J Am Dent Assoc 122:63-69, 1991
56. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
57. LeVeque FG, Montgomery M, Potter D: A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 11:1124-1113, 1993
58. Johnson JT, Ferretti GA, Nethery WJ: Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390-395, 1993
59. Scarantino CW, Leveque FG, Scott CB, et al: A phase III study of concomitant oral pilocarpin to reduce hyposalivation and mucositis associated with curative radiation therapy in head and neck cancer. RTOG 9709. Proc ASCO 20:225a, 2001 (abstr)
60. Fisher JJ, Scott CB, Scarantino CW, et al: Phase III quality of life study: Reduction in hyposalivation does not improve QOL for head and neck cancer patients post radiation therapy. Proc ASCO 21:356a, 2002 (abstr)
61. Atkinson JC, Shiroky JB, Macinski A, et al: Effects of furosemide on the oral cavity. Gerodontology 8:23-26, 1989
62. Wang SL, Zhao ZT, Li J, et al: Investigation of the clinical value of total saliva flow rates. Arch Oral Biol 43:39-43, 1998
63. Screebny LM, Valdini A, Xerostomia: Part I: Relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66:451-458, 1988
64. Speight PM, Kaul A, Melson RD: Measurements of whole unstimulated salivary flow in the diagnosis of Sjogren syndrome. Ann Rheum Dis 51:499-502, 1992
65. Navazesh M, Christensen C, Brightman V: Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res 71:1363-1369, 1992
66. Rhodus NL, Moller K: Dysphagia in post-radiation therapy head and neck cancer patients with salivary gland dysfunction. A pilot study Cancer Res Cont Ther 4:49-55, 1994